Actemra (tocilizumab) and Kevzara (sarilumab) have comparable safety profiles in older adults with rheumatoid arthritis, with no clinically meaningful differences in adverse events between the two IL-6 inhibitors.
Direct Comparative Safety Evidence
The most direct head-to-head comparison shows equivalent safety between these agents. The ASCERTAIN trial directly compared sarilumab and tocilizumab and found no clinically meaningful differences in treatment-emergent adverse events 1. Both drugs demonstrated similar patterns of laboratory changes including decreased neutrophils and platelets, and increased transaminases and lipids 1. Importantly, there was no association between decreased absolute neutrophil counts and increased infection incidence with either agent 1.
Age-Specific Safety Considerations
For older adults specifically, both agents require similar caution:
Kevzara (sarilumab): The FDA label notes that among patients ≥65 years, the frequency of serious infections was higher compared to younger patients, though no overall safety differences were observed between age groups 2. The label specifically states "caution should be used when treating the elderly" 2.
Actemra (tocilizumab): Recent Japanese postmarketing surveillance data from 2025 suggests tocilizumab is generally well tolerated in older patients with RA and does not increase cardiovascular events or malignancies 3. However, one 2024 study found tocilizumab had an increased risk of serious infections compared to TNF inhibitors (aHR 2.493 [1.275-4.876]) 4, and in patients ≥75 years, etanercept showed better safety than tocilizumab (aRR 2.40 [1.24-4.61] for tocilizumab) 4.
Key Safety Patterns Common to Both
Both IL-6 inhibitors share these safety considerations:
- Infection risk: Elevated compared to general population (aHR 3.65 [3.13-4.25] for herpes zoster with b/tsDMARDs) 4
- Laboratory monitoring: Both require monitoring for neutropenia, thrombocytopenia, elevated transaminases, and lipid changes 1
- Elderly population: Higher baseline infection risk necessitates heightened vigilance with either agent 2
Clinical Decision Algorithm
Choose either agent based on:
- Route preference: Tocilizumab offers both IV and subcutaneous formulations 5; sarilumab is subcutaneous only 2
- Dosing convenience: Tocilizumab IV every 4 weeks vs sarilumab subcutaneous every 2 weeks
- Prior exposure: If one agent failed due to intolerance, cycling to the other IL-6 inhibitor is reasonable 6
- Comorbidities: Both have similar cardiovascular and malignancy profiles in older adults 3
Important Caveats
- Network meta-analysis evidence shows both agents provide clinically important ACR50 responses: sarilumab (OR 3.11 [1.25-7.76]) and tocilizumab 8 mg/kg IV (OR 10.03 [3.65-31.27]) compared to placebo 7
- The slightly higher odds ratio for tocilizumab 8 mg/kg should be interpreted cautiously as this reflects efficacy, not safety superiority
- Most critical point: The 2026 EULAR safety review found one study showing increased serious infection risk with tocilizumab versus TNF inhibitors specifically 4, but this was not consistently replicated across all studies
Bottom line for older adults: Neither agent demonstrates clear safety superiority. Select based on practical factors (route, dosing frequency) and monitor both agents identically for infections, laboratory abnormalities, and age-related complications.